CFDE Data Portal | Search DNAAF2

	Label	Description
	DNAAF2 Gene (Entity type)	ENSG00000165506 - dynein axonemal assembly factor 2
	DNAAF2 associations Collection (Entity type)	Associations for DNAAF2_associations
	DNAAF2 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE195663 cisplatin 7 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE102757 1 V 0 PANOBINOSTAT MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 11 V 6 SULFORAPHANE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 6 V 5 CRIZOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 11 V 9 CRIZOTINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE228263 FDX1 overexpression SU-DHL-4 Elesclomol 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE228263 elesclomol SU-DHL-4 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

DNAAF2

ENSG00000165506 - dynein axonemal assembly factor 2

DNAAF2 associations

Associations for DNAAF2_associations

DNAAF2 associations.tsv

A file from IDG as part of the Harmonizome project

GSE195663 cisplatin 7 v 1 human dn

A Gene Set from LINCS

GSE102757 1 V 0 PANOBINOSTAT MOUSE UP

A Gene Set from LINCS

GSE48812 11 V 6 SULFORAPHANE HUMAN DN

A Gene Set from LINCS

GSE239844 6 V 5 CRIZOTINIB HUMAN DN

A Gene Set from LINCS

GSE239844 11 V 9 CRIZOTINIB HUMAN UP

A Gene Set from LINCS

GSE228263 FDX1 overexpression SU-DHL-4 Elesclomol 0 v 1 human dn

A Gene Set from LINCS

GSE228263 elesclomol SU-DHL-4 0 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.